Recombinant Human Prourokinase for Acute Ischemic Stroke in the Extended Window Selected by CT-Based Artificial Intelligence
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 826 participants.
Also called NCT07901842
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 826 participants
- Registry
-
NCT07901842
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07901842. Randomized; quadruple masking; primary purpose treatment. Start 2026-12-01 (anticipated); primary completion 2029-12-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Recombinant Human Prourokinase for Acute Ischemic Stroke in the Extended Window Selected by CT-Based Artificial Intelligence
- Acronym
- RAISE-AI
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Recombinant Human Prourokinase for Injection (rhPro-UK)
- Intervention (Drug)
- Matching Placebo for Recombinant Human Prourokinase
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Record details
- Record id
cardio:ct-nct07901842- Content hash
762548f6c52827b745f4c0b8e64e2fe1c954646fcd7692081a54cce32b46a400